We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

100 hedge funds and large institutions have $534M invested in Palvella Therapeutics in 2025 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 24 increasing their positions, 20 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

367% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 9

301% more capital invested

Capital invested by funds: $133M → $534M (+$401M)

208% more call options, than puts

Call options by funds: $984K | Put options by funds: $320K

49% more funds holding

Funds holding: 67 → 100 (+33)

23.63% more ownership

Funds ownership: 53.45% → 77.09% (+24%)

20% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 20

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
100
Holders Change
+33
Holders Change %
+49.25%
% of All Funds
1.31%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
42
Increased
24
Reduced
20
Closed
9
Calls
$984K
Puts
$320K
Net Calls
+$664K
Net Calls Change
+$396K

Top Buyers

Rank Fund Capital Flow
1
FLAM
First Light Asset Management
Minnesota
+$24.1M
2
BI
BVF Inc
California
+$20.7M
3
PA
Perceptive Advisors
New York
+$17.6M
4
Federated Hermes
Federated Hermes
Pennsylvania
+$15.1M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$14.8M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$12.8M
2
ASP
Adams Street Partners
Illinois
-$6.74M
3
SB
Samsara BioCapital
California
-$5.8M
4
WP
Woodline Partners
California
-$4.45M
5
SAM
Sectoral Asset Management
Quebec, Canada
-$2.07M
Name Holding Trade Value Shares
Change 		Change in
Stake
IC
26
Ikarian Capital
Texas
$4.06M +$2.89M +64,746 New
Northern Trust
27
Northern Trust
Illinois
$3.39M -$22.3K -500 -0.9%
Aberdeen Group
28
Aberdeen Group
United Kingdom
$3.21M +$2.29M +51,243 New
RA
29
Royce & Associates
New York
$3.1M -$1.12M -25,007 -34%
SAM
30
Sectoral Asset Management
Quebec, Canada
$3.08M -$2.07M -46,500 -49%
Invesco
31
Invesco
Georgia
$3.05M +$2.17M +48,610 New
JGC
32
J. Goldman & Co
New York
$2.55M -$696K -15,598 -28%
SPPAM
33
Summit Partners Public Asset Management
Massachusetts
$2.19M +$1.56M +34,895 New
Millennium Management
34
Millennium Management
New York
$1.68M -$12.8M -288,115 -91%
BFM
35
Boothbay Fund Management
New York
$1.6M +$1.14M +25,532 New
Raymond James Financial
36
Raymond James Financial
Florida
$1.49M +$1.06M +23,833 +476,660%
Wellington Management Group
37
Wellington Management Group
Massachusetts
$1.49M +$1.06M +23,702 New
Charles Schwab
38
Charles Schwab
California
$1.32M – – –
Mariner
39
Mariner
Kansas
$1.3M +$924K +20,722 New
UBS Group
40
UBS Group
Switzerland
$1.28M -$1.01M -22,710 -53%
CAM
41
Cresset Asset Management
Illinois
$1.09M -$155K -3,487 -17%
Bank of New York Mellon
42
Bank of New York Mellon
New York
$1.01M +$113K +2,523 +18%
N
43
Nuveen
North Carolina
$796K +$169K +3,800 +43%
DAM
44
Deltec Asset Management
New York
$784K – – –
CCM
45
Catalio Capital Management
New York
$753K +$536K +12,010 New
EP
46
Eversept Partners
New York
$711K +$506K +11,343 New
Jane Street
47
Jane Street
New York
$628K +$447K +10,017 New
ACA
48
Apis Capital Advisors
New York
$627K +$446K +10,000 New
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
$619K -$3.79K -85 -0.9%
Barclays
50
Barclays
United Kingdom
$613K -$107K -2,403 -20%
1
2
3 4 5

PVLA Hedge Fund Activity: Q3 2025 in Review

100 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q3 2025, worth a combined $534M — up 301% from $133M a quarter earlier.

Buyers outnumbered sellers: 42 funds opened new PVLA positions and 9 closed out — a net gain of 33 holders — while 24 added to existing stakes and 20 trimmed.

The largest buyer was First Light Asset Management, opening a new position worth an estimated $24.1M. The largest seller was Millennium Management, cutting an estimated $12.8M.

  • 100 institutional investors held Palvella Therapeutics (PVLA) as of Q3 2025, up from 67 in Q2 2025.
  • Funds reported $534M of Palvella Therapeutics stock for Q3 2025, up 301% quarter-over-quarter.
  • 42 funds opened new Palvella Therapeutics positions in Q3 2025 and 9 closed out, a net change of +33 holders.
  • The largest Palvella Therapeutics buyer in Q3 2025 was First Light Asset Management, an estimated $24.1M added.
  • The largest Palvella Therapeutics seller in Q3 2025 was Millennium Management, an estimated $12.8M sold.

Based on aggregated 13F filings for Q3 2025.